Table 1.
Relationships between CONUT-CTC score and clinicopathological characteristics of 160 CRC patients
| Characteristics | CONUT-CTC score [n (%)] | χ2 value | P value | ||
|---|---|---|---|---|---|
| Score 0 (n = 34) |
Score 1 (n = 61) |
Score 2 (n = 65) |
|||
| Gender | 0.195 | 0.907 | |||
| Male | 18 (52.94) | 35 (57.38) | 37 (56.92) | ||
| Female | 16 (47.06) | 26 (42.62) | 28 (43.08) | ||
| Age (years) | 0.425 | 0.808 | |||
| <60 | 16 (47.06) | 32 (52.46) | 35 (53.85) | ||
| ≥60 | 18 (52.94) | 29 (47.54) | 30 (46.15) | ||
| BMI (kg/m2) | 4.755 | 0.313 | |||
| <18.5 | 15 (44.12) | 22 (36.07) | 32 (49.23) | ||
| ≥18.5, <25.0 | 13 (38.24) | 33 (54.10) | 24 (36.92) | ||
| ≥25.0 | 6 (17.64) | 6 (9.83) | 9 (13.85) | ||
| Tumour location | 3.981 | 0.137 | |||
| Colon | 16 (47.06) | 41 (67.21) | 36 (55.38) | ||
| Rectal | 18 (52.94) | 20 (32.79) | 29 (44.62) | ||
| Tumour size (cm) | 1.011 | 0.603 | |||
| <3 | 17 (50.00) | 37 (60.66) | 37 (56.92) | ||
| ≥3 | 17 (50.00) | 24 (39.34) | 28 (43.08) | ||
| Histopathological type | 1.114 | 0.573 | |||
| Well-moderate | 22 (64.71) | 36 (59.02) | 35 (53.85) | ||
| Poor | 12 (35.29) | 25 (40.98) | 30 (46.15) | ||
| Depth of tumour invasion | 7.406 | 0.025* | |||
| T1-T2 | 10 (29.41) | 8 (13.11) | 6 (9.23) | ||
| T3-T4 | 24 (70.59) | 53 (86.89) | 59 (90.77) | ||
| Lymph node metastasis | 5.115 | 0.078 | |||
| N0-1 | 27 (79.41) | 41 (67.21) | 37 (56.92) | ||
| N2-3 | 7 (20.59) | 20 (32.79) | 28 (43.08) | ||
| pTNM stage | 6.831 | 0.033* | |||
| I-II | 23 (67.65) | 39 (63.93) | 29 (44.62) | ||
| III | 11 (32.35) | 22 (36.07) | 36 (55.38) | ||
| Lymphatic vessel invasion | 12.538 | 0.002* | |||
| Negative | 27 (79.41) | 40 (65.58) | 29 (44.62) | ||
| Positive | 7 (20.59) | 21 (34.42) | 36 (55.38) | ||
| Venous invasion | 17.944 | <0.001* | |||
| Negative | 29 (85.29) | 37 (60.66) | 32 (49.23) | ||
| Positive | 5 (14.71) | 24 (39.34) | 33 (50.77) | ||
| Severe complication | 1.539 | 0.463 | |||
| Absence | 28 (82.35) | 50 (81.97) | 58 (89.23) | ||
| Presence | 6 (17.65) | 11 (18.03) | 7 (10.77) | ||
| Adjuvant chemotherapy | 4.401 | 0.111 | |||
| No | 21 (61.76) | 31 (50.82) | 26 (40.00) | ||
| Yes | 13 (38.24) | 30 (49.18) | 39 (60.00) | ||
| Preoperative CEA (ng/ml) | 1.389 | 0.499 | |||
| <5 | 25 (73.53) | 39 (63.93) | 47 (72.31) | ||
| ≥5 | 9 (26.47) | 22 (36.07) | 18 (27.69) | ||
| Preoperative CA125 ( U/ml) | 0.169 | 0.919 | |||
| <35 | 26 (76.47) | 46 (75.41) | 51 (78.46) | ||
| ≥35 | 8 (23.53) | 15 (24.59) | 14 (21.54) | ||
| Preoperative CA199 ( U/ml) | 0.415 | 0.813 | |||
| <37 | 23 (67.65) | 45 (73.77) | 47 (72.31) | ||
| ≥37 | 11 (32.35) | 16 (26.23) | 18 (27.69) | ||
Notes: *indicates P<0.05. CRC, colorectal cancer; CONUT, controlling nutritional status; CTC, circulating tumour cell; BMI, body mass index; TNM, tumour-node- metastasis; CEA, carcinoembryonic antigen; CA125, carbohydrate antigen 125; CA199; carbohydrate antigen 199.